Anti-arthritic effects of KF20444, a new immunosuppressive compound inhibiting dihydroorotate dehydrogenase, on rat collagen-induced arthritis

Inflammation Research

Volumn 50, Issue 1, 2001, Pages 24-31

  Kobayashi, K ^a   Nakashima, A ^a   Nagata, H ^a   Nakajima, H ^a   Yamaguchi, K ^a   Sato, S ^a   Miki, I ^a  

^a Drug Discovery Research Lab   (Japan)

Author keywords

Cell cycle; Collagen induced arthritis; Dihydroorotate dehydrogenase; KF20444; Rheumatoid arthritis

Indexed keywords

6,7 DIHYDRO 10 FLUORO 3 (2 FLUOROPHENYL) 5H BENZO[6,7]CYCLOHEPTA[1,2 B]QUINOLINE 8 CARBOXYLIC ACID; BREQUINAR; COLLAGEN; COLLAGEN ANTIBODY; DIHYDROOROTATE DEHYDROGENASE; KF 20444; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTHRITIS; ARTICLE; BONE EROSION; CELL CYCLE; CELL CYCLE S PHASE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME INHIBITION; FEMALE; NONHUMAN; PANNUS; RAT; RHEUMATOID ARTHRITIS; SCORING SYSTEM;

ANIMALS; ARTHRITIS; AUTOANTIBODIES; BIPHENYL COMPOUNDS; CELL CYCLE; CELL DIVISION; COLLAGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JURKAT CELLS; LIVER; LYMPHOCYTE SPECIFIC PROTEIN TYROSINE KINASE P56(LCK); OXIDOREDUCTASES; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; RATS; WEIGHT LOSS;

EID: 0035136986     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050720     Document Type: Article

References (43)

1. The immunosuppressive effect of new immunosuppressant, KF20444
2. Effect of a new immunosuppressive agent, KF20444, in rat cardiac transplantation
3. Potent immunosuppressive effects by a newly synthesized compound KF20444
4. Activity of a novel 4-quinolinecarboxylic acid, NSC 368390 [6-fluoro-2-(2′-fluoro-1,1′-biphenyl-4-yl)-3-methyl-4quinolinecar boxylic acid sodium salt], against experimental tumors
5. The unique immunosuppressive activity of brequinar sodium
6. The prolongation of concordant hamster-to-rat cardiac xenografts by brequinar sodium
7. The effect of a new immunosuppressive drug, brequinar sodium, on heart, liver, and kidney allograft rejection in the rat
8. Mechanism of action of the novel anticancer agent 6-fluoro-2-(2′-fluoro-1,1′-biphenyl-4-yl)-3-methyl-4-quinolinecar boxylic acid sodium salt (NSC 368390): Inhibition of de novo pyrimidine nucleotide biosynthesis
9. The development of Brequinar as an immunosuppressive drug for transplantation
10. In vitro and in vivo mechanisms of action of the antiproliferative and immunosuppressive agent, brequinar sodium
11. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis
12. Cell cycle regulation and inhibition of de novo pyrimidine biosynthesis by leflunomide
13. Disease modifying activity of HWA 486 in rat adjuvant-induced arthritis
14. Immunomodulation of rat antigen-induced arthritis by leflunomide alone and in combination with cyclosporin A
15. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial
16. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis
17. Autoimmunity to type II collagen an experimental model of arthritis
18. Collagen arthritis as a relevant model for rheumatoid arthritis
19. Interleukin 1 mediated acceleration of type II collagen-induced arthritis: Effects of anti-inflammatory or anti-arthritic drugs
20. Paradoxical effects of cyclosporin A on collagen arthritis in rats
21. A sensitive, nonradiometric assay for dihydroorotic acid dehydrogenase using anion-exchange high-performance liquid chromatography
22. Synthesis and protein-tyrosine kinase inhibitory activities of flavonoid analogues
23. c-src
24. A fluorescence polarization competition immunoassay for tyrosine kinases
25. Novel mechanisms of brequinar sodium immunosuppression on T cell activation
26. The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism
27. Inhibition of dihydroorotate dehydrogenase activity by brequinar sodium
28. Identification of a novel inhibitor (NSC 665564) of dihydroorotate dehydrogenase with a potency equivalent to brequinar
29. The cellular location of dihydroorotate dehydrogenase: Relation to de novo biosynthesis of pyrimidines
30. Inhibition of synthesis of pyrimidine nucleotides by 2-hydroxy-3-(3,3-dichloroallyl)-1,4-naphthoquinone
31. Superoxide production and electron transport in mitochondrial oxidation of dihydroorotic acid
32. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase
33. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide
34. Leflunomide, a reversible inhibitor of pyrimidine biosynthesis?
35. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJr/1pr mice
36. Maintaining genetic stability through TP53 mediated checkpoint control
37. A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage
38. Leflunomide, a novel immunomodulating drug, inhibits homotypic adhesion of peripheral blood and synovial fluid mononuclear cells in rheumatoid arthritis
39. A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner
40. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression
41. A novel mechanism of action of the immunomodulatory drug, leflunomide: Augmentation of the immunosuppressive cytokine, TGFbeta 1, and suppression of the immunostimulatory cytokine, IL-2
42. Synthesis, structure-activity relationships, and pharmacokinetic properties of dihydroorotate dehydrogenase inhibitors: 2-cyano-3-cyclopropyl-3-hydroxy-N- [3′-methyl-4′-(trifluoromethyl)phenyl] propenamide and related compounds
43. Effects of leflunomide on immune responses and models of inflammation